Sharps Compliance Corp. (SMED) Stock Competitors & Peer Comparison
See (SMED) competitors and their performances in Stock Market.
Peer Comparison Table: Waste Management Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SMED | $8.75 | +0.00% | 0 | 36.46 | $0.24 | N/A |
| WM | $223.57 | +3.44% | 88.9B | 31.98 | $6.92 | +1.61% |
| RSG | $212.44 | +3.66% | 64.6B | 30.14 | $6.97 | +1.18% |
| WCN | $158.41 | +3.06% | 40B | 38.42 | $4.10 | +0.87% |
| GFLU | $70.30 | +4.32% | 25B | -91.90 | -$0.77 | N/A |
| CLH | $291.70 | +4.79% | 15.2B | 38.96 | $7.39 | N/A |
| GFL | $36.27 | +3.93% | 12.4B | 96.51 | $0.37 | +0.18% |
| SRCL | $61.98 | +0.83% | 5.8B | 158.92 | $0.39 | N/A |
| CWST | $89.49 | +5.81% | 5.5B | 798.27 | $0.11 | N/A |
| NVRI | $20.87 | +4.98% | 1.8B | -10.34 | -$2.05 | +71.29% |
Stock Comparison
SMED vs WM Comparison June 2026
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, WM has a market cap of 88.9B. Regarding current trading prices, SMED is priced at $8.75, while WM trades at $223.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas WM's P/E ratio is 31.98. In terms of profitability, SMED's ROE is +0.34%, compared to WM's ROE of +0.29%. Regarding short-term risk, SMED is less volatile compared to WM. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check WM's competition here
SMED vs RSG Comparison June 2026
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, RSG has a market cap of 64.6B. Regarding current trading prices, SMED is priced at $8.75, while RSG trades at $212.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas RSG's P/E ratio is 30.14. In terms of profitability, SMED's ROE is +0.34%, compared to RSG's ROE of +0.18%. Regarding short-term risk, SMED is less volatile compared to RSG. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check RSG's competition here
SMED vs WCN Comparison June 2026
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, WCN has a market cap of 40B. Regarding current trading prices, SMED is priced at $8.75, while WCN trades at $158.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas WCN's P/E ratio is 38.42. In terms of profitability, SMED's ROE is +0.34%, compared to WCN's ROE of +0.13%. Regarding short-term risk, SMED is less volatile compared to WCN. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check WCN's competition here
SMED vs GFLU Comparison June 2026
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, GFLU has a market cap of 25B. Regarding current trading prices, SMED is priced at $8.75, while GFLU trades at $70.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas GFLU's P/E ratio is -91.90. In terms of profitability, SMED's ROE is +0.34%, compared to GFLU's ROE of N/A. Regarding short-term risk, SMED is less volatile compared to GFLU. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check GFLU's competition here
SMED vs CLH Comparison June 2026
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, CLH has a market cap of 15.2B. Regarding current trading prices, SMED is priced at $8.75, while CLH trades at $291.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas CLH's P/E ratio is 38.96. In terms of profitability, SMED's ROE is +0.34%, compared to CLH's ROE of +0.14%. Regarding short-term risk, SMED is less volatile compared to CLH. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check CLH's competition here
SMED vs GFL Comparison June 2026
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, GFL has a market cap of 12.4B. Regarding current trading prices, SMED is priced at $8.75, while GFL trades at $36.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas GFL's P/E ratio is 96.51. In terms of profitability, SMED's ROE is +0.34%, compared to GFL's ROE of +0.03%. Regarding short-term risk, SMED is less volatile compared to GFL. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check GFL's competition here
SMED vs SRCL Comparison June 2026
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, SRCL has a market cap of 5.8B. Regarding current trading prices, SMED is priced at $8.75, while SRCL trades at $61.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas SRCL's P/E ratio is 158.92. In terms of profitability, SMED's ROE is +0.34%, compared to SRCL's ROE of -0.01%. Regarding short-term risk, SMED is more volatile compared to SRCL. This indicates potentially higher risk in terms of short-term price fluctuations for SMED.Check SRCL's competition here
SMED vs CWST Comparison June 2026
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, CWST has a market cap of 5.5B. Regarding current trading prices, SMED is priced at $8.75, while CWST trades at $89.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas CWST's P/E ratio is 798.27. In terms of profitability, SMED's ROE is +0.34%, compared to CWST's ROE of +0.00%. Regarding short-term risk, SMED is less volatile compared to CWST. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check CWST's competition here
SMED vs NVRI Comparison June 2026
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, NVRI has a market cap of 1.8B. Regarding current trading prices, SMED is priced at $8.75, while NVRI trades at $20.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas NVRI's P/E ratio is -10.34. In terms of profitability, SMED's ROE is +0.34%, compared to NVRI's ROE of +0.37%. Regarding short-term risk, SMED is less volatile compared to NVRI. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check NVRI's competition here
SMED vs HCCI Comparison June 2026
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, HCCI has a market cap of 1.1B. Regarding current trading prices, SMED is priced at $8.75, while HCCI trades at $45.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas HCCI's P/E ratio is 14.22. In terms of profitability, SMED's ROE is +0.34%, compared to HCCI's ROE of +0.22%. Regarding short-term risk, SMED is more volatile compared to HCCI. This indicates potentially higher risk in terms of short-term price fluctuations for SMED.Check HCCI's competition here
SMED vs HSC Comparison June 2026
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, HSC has a market cap of 729.6M. Regarding current trading prices, SMED is priced at $8.75, while HSC trades at $9.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas HSC's P/E ratio is -5.08. In terms of profitability, SMED's ROE is +0.34%, compared to HSC's ROE of -0.70%. Regarding short-term risk, SMED is less volatile compared to HSC. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check HSC's competition here
SMED vs MEG Comparison June 2026
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, MEG has a market cap of 565.7M. Regarding current trading prices, SMED is priced at $8.75, while MEG trades at $15.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas MEG's P/E ratio is -120.31. In terms of profitability, SMED's ROE is +0.34%, compared to MEG's ROE of +0.01%. Regarding short-term risk, SMED is less volatile compared to MEG. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check MEG's competition here
SMED vs PESI Comparison June 2026
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, PESI has a market cap of 183.2M. Regarding current trading prices, SMED is priced at $8.75, while PESI trades at $9.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas PESI's P/E ratio is -12.49. In terms of profitability, SMED's ROE is +0.34%, compared to PESI's ROE of -0.34%. Regarding short-term risk, SMED is less volatile compared to PESI. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check PESI's competition here
SMED vs YDDL Comparison June 2026
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, YDDL has a market cap of 125.1M. Regarding current trading prices, SMED is priced at $8.75, while YDDL trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas YDDL's P/E ratio is 11.87. In terms of profitability, SMED's ROE is +0.34%, compared to YDDL's ROE of +0.36%. Regarding short-term risk, SMED is less volatile compared to YDDL. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check YDDL's competition here
SMED vs ESGL Comparison June 2026
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, ESGL has a market cap of 80.1M. Regarding current trading prices, SMED is priced at $8.75, while ESGL trades at $1.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas ESGL's P/E ratio is -31.50. In terms of profitability, SMED's ROE is +0.34%, compared to ESGL's ROE of -0.06%. Regarding short-term risk, SMED is less volatile compared to ESGL. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check ESGL's competition here
SMED vs LICY Comparison June 2026
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, LICY has a market cap of 29.9M. Regarding current trading prices, SMED is priced at $8.75, while LICY trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas LICY's P/E ratio is -0.15. In terms of profitability, SMED's ROE is +0.34%, compared to LICY's ROE of -0.41%. Regarding short-term risk, SMED is less volatile compared to LICY. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check LICY's competition here
SMED vs QRHC Comparison June 2026
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, QRHC has a market cap of 29.5M. Regarding current trading prices, SMED is priced at $8.75, while QRHC trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas QRHC's P/E ratio is -4.12. In terms of profitability, SMED's ROE is +0.34%, compared to QRHC's ROE of -0.18%. Regarding short-term risk, SMED is less volatile compared to QRHC. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check QRHC's competition here
SMED vs AMBI Comparison June 2026
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, AMBI has a market cap of 24.4M. Regarding current trading prices, SMED is priced at $8.75, while AMBI trades at $0.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas AMBI's P/E ratio is -44.00. In terms of profitability, SMED's ROE is +0.34%, compared to AMBI's ROE of -0.02%. Regarding short-term risk, SMED is less volatile compared to AMBI. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check AMBI's competition here
SMED vs ENGS Comparison June 2026
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, ENGS has a market cap of 23.5M. Regarding current trading prices, SMED is priced at $8.75, while ENGS trades at $1.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas ENGS's P/E ratio is -7.17. In terms of profitability, SMED's ROE is +0.34%, compared to ENGS's ROE of +0.28%. Regarding short-term risk, SMED is less volatile compared to ENGS. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check ENGS's competition here
SMED vs CHRA Comparison June 2026
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, CHRA has a market cap of 20.3M. Regarding current trading prices, SMED is priced at $8.75, while CHRA trades at $5.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas CHRA's P/E ratio is -0.15. In terms of profitability, SMED's ROE is +0.34%, compared to CHRA's ROE of +20.59%. Regarding short-term risk, SMED is more volatile compared to CHRA. This indicates potentially higher risk in terms of short-term price fluctuations for SMED.Check CHRA's competition here
SMED vs LNZA Comparison June 2026
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, LNZA has a market cap of 17.3M. Regarding current trading prices, SMED is priced at $8.75, while LNZA trades at $7.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas LNZA's P/E ratio is -0.55. In terms of profitability, SMED's ROE is +0.34%, compared to LNZA's ROE of -12.68%. Regarding short-term risk, SMED is less volatile compared to LNZA. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check LNZA's competition here
SMED vs AQMS Comparison June 2026
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, AQMS has a market cap of 11.2M. Regarding current trading prices, SMED is priced at $8.75, while AQMS trades at $3.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas AQMS's P/E ratio is -0.54. In terms of profitability, SMED's ROE is +0.34%, compared to AQMS's ROE of -1.85%. Regarding short-term risk, SMED is less volatile compared to AQMS. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check AQMS's competition here
SMED vs AWX Comparison June 2026
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, AWX has a market cap of 9.9M. Regarding current trading prices, SMED is priced at $8.75, while AWX trades at $2.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas AWX's P/E ratio is 18.14. In terms of profitability, SMED's ROE is +0.34%, compared to AWX's ROE of +0.02%. Regarding short-term risk, SMED is more volatile compared to AWX. This indicates potentially higher risk in terms of short-term price fluctuations for SMED.Check AWX's competition here
SMED vs CHNR Comparison June 2026
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, CHNR has a market cap of 5.4M. Regarding current trading prices, SMED is priced at $8.75, while CHNR trades at $4.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas CHNR's P/E ratio is -30.43. In terms of profitability, SMED's ROE is +0.34%, compared to CHNR's ROE of -0.01%. Regarding short-term risk, SMED is less volatile compared to CHNR. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check CHNR's competition here
SMED vs GWAV Comparison June 2026
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, GWAV has a market cap of 2.9M. Regarding current trading prices, SMED is priced at $8.75, while GWAV trades at $3.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas GWAV's P/E ratio is 0.02. In terms of profitability, SMED's ROE is +0.34%, compared to GWAV's ROE of -0.89%. Regarding short-term risk, SMED is less volatile compared to GWAV. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check GWAV's competition here
SMED vs DXST Comparison June 2026
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, DXST has a market cap of 2.2M. Regarding current trading prices, SMED is priced at $8.75, while DXST trades at $3.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas DXST's P/E ratio is -6.80. In terms of profitability, SMED's ROE is +0.34%, compared to DXST's ROE of -0.04%. Regarding short-term risk, SMED is less volatile compared to DXST. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check DXST's competition here
SMED vs CDTG Comparison June 2026
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, CDTG has a market cap of 1.7M. Regarding current trading prices, SMED is priced at $8.75, while CDTG trades at $2.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas CDTG's P/E ratio is -0.17. In terms of profitability, SMED's ROE is +0.34%, compared to CDTG's ROE of -0.29%. Regarding short-term risk, SMED is less volatile compared to CDTG. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check CDTG's competition here
SMED vs CVA Comparison June 2026
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, CVA has a market cap of 0. Regarding current trading prices, SMED is priced at $8.75, while CVA trades at $20.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas CVA's P/E ratio is N/A. In terms of profitability, SMED's ROE is +0.34%, compared to CVA's ROE of -0.08%. Regarding short-term risk, SMED is less volatile compared to CVA. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check CVA's competition here
SMED vs ECOL Comparison June 2026
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, ECOL has a market cap of 0. Regarding current trading prices, SMED is priced at $8.75, while ECOL trades at $47.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas ECOL's P/E ratio is N/A. In terms of profitability, SMED's ROE is +0.34%, compared to ECOL's ROE of +0.01%. Regarding short-term risk, SMED is more volatile compared to ECOL. This indicates potentially higher risk in terms of short-term price fluctuations for SMED.Check ECOL's competition here
SMED vs ECOLW Comparison June 2026
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, ECOLW has a market cap of 0. Regarding current trading prices, SMED is priced at $8.75, while ECOLW trades at $5.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas ECOLW's P/E ratio is N/A. In terms of profitability, SMED's ROE is +0.34%, compared to ECOLW's ROE of +0.01%. Regarding short-term risk, SMED is more volatile compared to ECOLW. This indicates potentially higher risk in terms of short-term price fluctuations for SMED.Check ECOLW's competition here
SMED vs NES Comparison June 2026
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, NES has a market cap of 0. Regarding current trading prices, SMED is priced at $8.75, while NES trades at $2.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas NES's P/E ratio is -1.32. In terms of profitability, SMED's ROE is +0.34%, compared to NES's ROE of -0.29%. Regarding short-term risk, SMED is less volatile compared to NES. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check NES's competition here